Skip to main content
ScholarsBetaWeill Cornell Medicine

Highlights

  1. 1
    JAMA internal medicine · 2025
    DBDanielle Brandman
    PMID: 39585671DOIeCommonsSenior author25 citations
  2. 2
    Hepatology communications · 2023
    DBDanielle Brandman
    PMID: 36724121PMCID: PMC9894348DOISenior author14 citations
  3. 3
    Alimentary pharmacology & therapeutics · 2022
    DBDanielle Brandman
    PMID: 35302256PMCID: PMC9098681DOIFirst author16 citations

Publications

45 publications

Clinical research

3 studies

Active

3 studies
  • PI
    Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate MGL-3196 (Resmetirom) in Patients With MASH Who Have Undergone Liver Transplant for MASH Cirrhosis or Other Etiologies
    PHASE2 · Madrigal Pharmaceuticals, Inc. · OPEN TO ACCRUAL (as of 2026)
    MASH - Metabolic Dysfunction-Associated Steatohepatitis
    NCT07335601
  • PI
    Diagnostic Utility of coronary CTA in patients with End-Stage Liver Disease
    Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2026)
  • PI
    Post-transplant NASH protocol to assess the development of metabolic comorbidities and disease recurrence in those transplanted for NASH cirrhosis
    University of Chicago · OPEN TO ACCRUAL (as of 2024)

Mentoring

1 mentee
  • HH
    Haiyue He
    Postdoc mentee · 2019–2022

External relationships

Advisory/Scientific Board Member

Madrigal Pharmaceuticals, Inc.

Professional Services

UpToDate, Inc.